NASDAQ:CALA Calithera Biosciences (CALA) Stock Forecast, Price & News $0.35 +0.00 (+0.72%) (As of 09:30 AM ET) Add Compare Share Share Today's Range$0.35▼$0.3550-Day Range$0.02▼$0.3752-Week Range$0.01▼$5.10Volume356 shsAverage Volume201,050 shsMarket Capitalization$1.69 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Calithera Biosciences MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside3,641.0% Upside$13.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 stars 3.2 Analyst's Opinion Consensus RatingCalithera Biosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, Calithera Biosciences has a forecasted upside of 3,641.0% from its current price of $0.35.Amount of Analyst CoverageCalithera Biosciences has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CALA. Previous Next 0.0 Dividend Strength Dividend YieldCalithera Biosciences does not currently pay a dividend.Dividend GrowthCalithera Biosciences does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCalithera Biosciences has received a 68.66% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for cancer", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Calithera Biosciences is -1.11. Previous Next N/A News and Social Media Coverage Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Calithera Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of Calithera Biosciences is held by insiders.Percentage Held by InstitutionsOnly 33.73% of the stock of Calithera Biosciences is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Calithera Biosciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Calithera Biosciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Calithera Biosciences (NASDAQ:CALA) StockCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Read More Receive CALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CALA Stock News HeadlinesJune 1, 2023 | finance.yahoo.comCALA - Calithera Biosciences, Inc.May 31, 2023 | americanbankingnews.comCalithera Biosciences (NASDAQ:CALA) Stock Price Passes Above 50 Day Moving Average of $0.08June 8, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 31, 2023 | americanbankingnews.comCalithera Biosciences (NASDAQ:CALA) Coverage Initiated by Analysts at StockNews.comMay 24, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Calithera Biosciences (NASDAQ:CALA)May 20, 2023 | finanznachrichten.deCalithera Biosciences, Inc.: Calithera Biosciences Announces Update on Complete Liquidation and DissolutionMay 19, 2023 | travel.usnews.comCala MarioluMay 19, 2023 | seekingalpha.comCalithera Biosciences plans special meeting to seek approval for liquidation and dissolution planJune 8, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.May 19, 2023 | finance.yahoo.comCalithera Biosciences Announces Update on Complete Liquidation and DissolutionMay 15, 2023 | americanbankingnews.comCalithera Biosciences (NASDAQ:CALA) Receives New Coverage from Analysts at StockNews.comMay 13, 2023 | travel.usnews.comCala LlombardsMay 12, 2023 | investing.comCalithera Biosciences Inc (CALA) Earnings Dates & ReportsApril 29, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Calithera Biosciences (NASDAQ:CALA)April 6, 2023 | americanbankingnews.comCalithera Biosciences (NASDAQ:CALA) Now Covered by StockNews.comMarch 28, 2023 | americanbankingnews.comCalithera Biosciences (CALA) Set to Announce Earnings on WednesdayMarch 28, 2023 | americanbankingnews.comCalithera Biosciences (CALA) Scheduled to Post Earnings on WednesdayJanuary 11, 2023 | marketwatch.comCalithera Biosciences Shares Plummet on Liquidation Plans >CALAJanuary 11, 2023 | marketwatch.comCalithera Biosciences to Liquidate >CALAJanuary 10, 2023 | finance.yahoo.comBiotech company Calithera plans its own death. Will others follow?January 9, 2023 | finanznachrichten.deCalithera Biosciences, Inc.: Calithera Biosciences Announces Board Approval of Complete Liquidation and DissolutionJanuary 9, 2023 | markets.businessinsider.comCalithera Biosciences Board Of Directors Determine Dissolution Of CompanyJanuary 9, 2023 | finance.yahoo.comCalithera Biosciences Stock Nosedives On Complete Liquidation, DissolutionJanuary 9, 2023 | finance.yahoo.comCalithera Biosciences Announces Board Approval of Complete Liquidation and DissolutionNovember 15, 2022 | finanznachrichten.deCalithera Biosciences, Inc.: Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business UpdateNovember 15, 2022 | seekingalpha.comCalithera Biosciences, Inc. (CALA) Q3 2022 Earnings Call TranscriptNovember 15, 2022 | finance.yahoo.comCalithera Biosciences Reports Third Quarter 2022 Financial Results and Business UpdateSee More Headlines CALA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CALA Company Calendar Last Earnings11/08/2021Today6/08/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CALA CUSIPN/A CIK1496671 Webwww.calithera.com Phone(650) 870-1000FaxN/AEmployees8Year Founded2010Price Target and Rating Average Stock Price Forecast$13.00 High Stock Price Forecast$18.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+3,668.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($25.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,336.25% Return on Assets-98.17% Debt Debt-to-Equity RatioN/A Current Ratio3.60 Quick Ratio3.60 Sales & Book Value Annual Sales$9.75 million Price / Sales0.17 Cash FlowN/A Price / Cash FlowN/A Book Value($0.40) per share Price / Book-0.86Miscellaneous Outstanding Shares4,870,000Free Float4,550,000Market Cap$1.68 million OptionableOptionable Beta0.60 Social Links Key ExecutivesDr. Susan M. Molineaux Ph.D. (Age 69)Founder, CEO, Pres & Director Comp: $625.81kMs. Stephanie Wong (Age 49)CFO & Sec. Comp: $752.42kDr. Christopher J. Molineaux Ph.D. (Age 70)Sr. VP of Devel. Mr. Frank Parlati Ph.D. (Age 54)Sr. VP of Research Dr. Susan B. Demo Ph.D.Sr. VP of R&D OperationsDr. Allison Dillon Ph.D.Sr. VP of Commercial & Portfolio StrategyMore ExecutivesKey CompetitorsContraFectNASDAQ:CFRXScopus BioPharmaNASDAQ:SCPSLexaria BioscienceNASDAQ:LEXXAthenexNASDAQ:ATNXStatera BiopharmaNASDAQ:STABView All CompetitorsInsidersDeepika PakianathanSold 121,333 sharesTotal: $47,319.87 ($0.39/share)View All Insider Transactions CALA Stock - Frequently Asked Questions Should I buy or sell Calithera Biosciences stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CALA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CALA, but not buy additional shares or sell existing shares. View CALA analyst ratings or view top-rated stocks. What is Calithera Biosciences' stock price forecast for 2023? 3 analysts have issued 12 month target prices for Calithera Biosciences' shares. Their CALA share price forecasts range from $8.00 to $18.00. On average, they expect the company's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 3,668.1% from the stock's current price. View analysts price targets for CALA or view top-rated stocks among Wall Street analysts. How have CALA shares performed in 2023? Calithera Biosciences' stock was trading at $3.26 at the start of the year. Since then, CALA stock has decreased by 89.4% and is now trading at $0.3450. View the best growth stocks for 2023 here. When is Calithera Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our CALA earnings forecast. How were Calithera Biosciences' earnings last quarter? Calithera Biosciences, Inc. (NASDAQ:CALA) issued its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($3.00) EPS for the quarter, beating the consensus estimate of ($4.60) by $1.60. The biotechnology company had revenue of $6.75 million for the quarter. During the same period in the previous year, the company posted ($6.40) earnings per share. When did Calithera Biosciences' stock split? Shares of Calithera Biosciences reverse split on the morning of Wednesday, June 15th 2022. The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Calithera Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE). What is Calithera Biosciences' stock symbol? Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA." How do I buy shares of Calithera Biosciences? Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Calithera Biosciences' stock price today? One share of CALA stock can currently be purchased for approximately $0.35. How much money does Calithera Biosciences make? Calithera Biosciences (NASDAQ:CALA) has a market capitalization of $1.68 million and generates $9.75 million in revenue each year. The biotechnology company earns $-39,650,000.00 in net income (profit) each year or ($25.60) on an earnings per share basis. How can I contact Calithera Biosciences? Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.calithera.com. The biotechnology company can be reached via phone at (650) 870-1000 or via email at ir@calithera.com. This page (NASDAQ:CALA) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calithera Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.